Deferasirox
CAS No. : 201530-41-8
(Synonyms: ICL 670)
| Size | Price | Stock |
|---|---|---|
| 5mg | $55 | In-stock |
| 10mg | $77 | In-stock |
| 25mg | $99 | In-stock |
| 50mg | $154 | In-stock |
| 100mg | $231 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-17359 |
| M.Wt: | 373.36 |
| Formula: | C21H15N3O4 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 100 mg/mL |
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3]. In Vitro: In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower[1]. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent[2]. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner[3]. In Vivo: The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Deferasirox
- Cat. No.:
- HY-17359
- Quantity:
Your information is safe with us.